The 92% ORR data in pancreatic cancer is the primary catalyst, watch for ESMO presentation in October and Phase 3 design announcement in 2H 2026. The $1.0B cash runway removes near-term dilution risk. Monitor for any regulatory feedback on the registrational path and lung cancer monotherapy data later this year.
Drugs in focus
ERAS-0015
◆ Mixed Named in this press release- Impact
- Phase
- Phase 1
- Time to market
- ~3-5 years, assuming registration-enabling trials initiate in 2027 and a potential approval by ~2029-2030
- Next catalyst
- None dated
What to watchERAS-0015 Phase 1 data is genuinely strong (57-62% response rates in difficult-to-treat tumors) but the stock carries heavy legal baggage, a securities class action and patent-infringement allegations from Revolution Medicines. The stock recovered from its April 48% crash to ~$18; watch for the August 10, 2026 lead-plaintiff deadline and any developments in the Revolution Medicines patent dispute, which could swing shares sharply. The registration-enabling trial initiations in H1 2027 are the next major de-risking catalyst.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 11 $26.34entry
- T+1 · 3mo ago −2.89%α −3.14% · $25.58
- T+5 · 3mo ago −3.42%α −3.01% · $25.44
- T+20 · 2mo ago −8.88%α −7.82% · $24.00
- T+60 · 13d ago −12.00%α −11.51% · $23.18
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Tango Therapeutics reported Q2 2026 net loss of $0.37 per share, slightly wider than the $0.35 loss in Q2 2025, with zero collaboration revenue as the Gilead deal concluded. The key catalyst is the 92% objective response rate for vopimetostat plus daraxonrasib in MTAP-deleted pancreatic cancer, driving plans for a Phase 3 trial and a $1.0B cash runway through commercialization. The stock's move hinges on the ESMO data presentation and Phase 3 design finalization in 2H 2026, not the financial results themselves.
Key Financial Metrics
Key Facts
- Net loss of $55.3M ($0.37/share) for Q2 2026 vs $38.9M ($0.35/share) in Q2 2025
- Cash position of $1.0B as of June 30, 2026, expected to fund current operating plan
- Vopimetostat + daraxonrasib achieved 92% objective response rate and 90% six-month PFS in MTAP-deleted, RAS-mutant pancreatic cancer
- Company initiating dialogue with regulators for registrational path; Phase 3 trial design to be finalized in 2H 2026
- Phase 1/2 data to be presented at ESMO Congress October 23-27, 2026
- Appointed Fatma Ocak as Chief Commercialization Officer and Robert Azelby as Chairman of the Board
- Research and development expenses increased to $37.2M from $32.8M year-over-year
- General and administrative expenses doubled to $22.6M from $11.3M year-over-year
Financial Impact
Net loss widened by $16.4M year-over-year to $55.3M; cash burn rate approximately $50M per quarter; $1.0B cash runway provides ~5 years of funding at current burn
Risk Factors
- Clinical trial failure in Phase 3 or regulatory setback
- Dependence on Revolution Medicines' RAS(ON) inhibitors for combination therapy
- Widening losses and increasing G&A expenses without near-term revenue
- Competition from other PRMT5 inhibitors and RAS-targeting therapies
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3342532 |
Track record
27 reports on TNGX
3 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +29.28% at T+60 after the Jun 8, 2026 report. 5 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $24.22 Now $24.17 +0.21% settles Feb 16
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $24.50 Now $24.17 +1.35% settles Feb 12
- Nov 9, 20267d ago Press Release Neutral 5/10 Entry $22.74 Now $24.17 +6.29% settles Feb 5
- Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $21.50 Now $24.17 +12.42% settles Feb 4
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $20.87 Now $24.17 +15.81% settles Feb 3
- Nov 2, 202614d ago Institutional Cluster Neutral 2/10 Entry $23.17 Now $24.17 +4.32% settles Feb 1
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $23.17 Now $24.17 +4.32% settles Feb 1
- Oct 23, 202624d ago 8-K Bullish 7/10 Entry $23.34 Now $24.17 +3.56% settles Jan 21
- Aug 11, 202613w ago 8-K Bearish 6/10 Entry $25.58 to $23.18 Now $24.17 +5.51% ▲ +9.38% +4.51% vs SPY
- Aug 11, 202613w ago 8-K Bullish 7/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers